![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/ERIS.png)
Share the post "Eris Lifesciences ‘s Q3 2024-25 Latest News: Revenue Grows by 49.59% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 49.59 % in the past year, decrease in net sales/revenue by -1.56 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 0.55 %. Marginal decrease of -37.67% in other income during this quarter. 🔹 Profit over the Year and quarter: Challenges in sustaining profitability for Eris Lifesciences Limited. Profit dropped by -14.32 % Year to Year, Eris Lifesciences Limited’s profitability dropped by -9.78 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS declined by -18.54 % Year to Year. EPS decreased by -8.62 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 486.297 Cr | Rs. 738.95 Cr | Rs. 727.45 Cr | -1.56 % | + 49.59 % |
| Expenses | Rs. 310.79 Cr | Rs. 476.66 Cr | Rs. 477.14 Cr | + 0.1 % | + 53.52 % |
| Operating Profit | Rs. 175.51 Cr | Rs. 262.29 Cr | Rs. 250.31 Cr | -4.57 % | + 42.62 % |
| OPM % | 36.09 % | 35.49 % | 34.41 % | -1.08 % | -1.68 % |
| Other Income | Rs. 4.197 Cr | Rs. 6.77 Cr | Rs. 4.22 Cr | -37.67 % | + 0.55 % |
| Interest | Rs. 18.12 Cr | Rs. 59.47 Cr | Rs. 57.17 Cr | -3.87 % | + 215.51 % |
| Depreciation | Rs. 45.72 Cr | Rs. 80.48 Cr | Rs. 81.2 Cr | + 0.89 % | + 77.6 % |
| Profit before tax | Rs. 115.87 Cr | Rs. 129.11 Cr | Rs. 116.16 Cr | -10.03 % | + 0.25 % |
| Tax % | 12.44 % | 25.37 % | 25.17 % | -0.2 % | + 12.73 % |
| Net Profit | Rs. 101.46 Cr | Rs. 96.35 Cr | Rs. 86.93 Cr | -9.78 % | -14.32 % |
| EPS in Rs | Rs. 7.54 | Rs. 6.72 | Rs. 6.14 | -8.63 % | -18.57 % |
Today, we’re looking at Eris Lifesciences Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 49.59 %. However, it did see a marginal slip of -1.56 % from the previous quarter. Expenses ticked up slightly by 0.1 % quarter-on-quarter, aligning with the annual rise of 53.52 %. Operating profit, while up 42.62 % compared to last year, faced a quarter-on-quarter dip of -4.57 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -1.68 %, but a shrinkage of -1.08 % sequentially. Other income fell by -37.67 % compared to the last quarter, despite an annual growth of 0.55 %. Interest expenses dropped significantly by -3.87 % from the previous quarter, yet the year-over-year increase remains at a moderate 215.51 %. Depreciation costs climbed by 0.89 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 77.6 %. Profit before tax grew annually by 0.25 % but saw a reduction from the preceding quarter by -10.03 %.
Tax expenses as a percentage of profits increased slightly by 12.73 % compared to last year, with a more notable quarter-on-quarter decrease of -0.2 %. Net profit fell by -14.32 % year-on-year but witnessed a -9.78 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -18.57 % but a quarterly fall of -8.63 %. In summary, Eris Lifesciences Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 486.297 Cr | Rs. 738.95 Cr | Rs. 727.45 Cr | -1.56 % | + 49.59 % |
| Expenses | Rs. 310.79 Cr | Rs. 476.66 Cr | Rs. 477.14 Cr | + 0.1 % | + 53.52 % |
| Operating Profit | Rs. 175.51 Cr | Rs. 262.29 Cr | Rs. 250.31 Cr | -4.57 % | + 42.62 % |
| Net Profit | Rs. 101.46 Cr | Rs. 96.35 Cr | Rs. 86.93 Cr | -9.78 % | -14.32 % |
| EPS in Rs | Rs. 7.54 | Rs. 6.72 | Rs. 6.14 | -8.63 % | -18.57 % |
In reviewing Eris Lifesciences Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 49.59 % year-on-year growth, although there was a slight dip of -1.56 % from the previous quarter. Expenses rose by 53.52 % compared to the previous year, with a 0.1 % increase quarter-on-quarter. Operating Profit surged by 42.62 % annually, and saw a -4.57 % decrease from the last quarter.
Net Profit showed yearly decrease of -14.32 %, and experienced a -9.78 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -18.57 % annually, however dipped by -8.63 % compared to the last quarter. In essence, while Eris Lifesciences Limited faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/RNBDENIMS.png)
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/SHESHAINDS.png)